Daratumumab Post Maintenance After Relapse in Multiple Myeloma. Report of 4 Cases
Insights in Blood Disorders · 2024
DOI: 10.33425/2771-9073.1012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Insights in Blood Disorders, 2024. Verfasst von Roberto Ovilla Martinez und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Multiple myeloma is considered incurable and requires combined and continuous treatments. We present 4 cases of patients with multiple myeloma who received daratumumab after the administration of combined therapy to achieve the best response possible, 3 patients debuted with high-risk disease. In this case series, 100% of patients achieved a strict complete response with undetectable Minimal Residual Disease (MRD) by flow cytometry, after the administration of daratumumab regardless of the scheme used in induction and consolidation, with or without autologous transplantation. After daratumumab, all patients received lenalidomide for at least 6 months with subsequent discontinuation. Follow-up included MRD.
Zitieren
APA
Martinez, R. O., Islas, P. B., Rangel, X. C., Celaya, A. D. L. P., Muniz, N. R., & Ibarra, M. A. (2024). Daratumumab Post Maintenance After Relapse in Multiple Myeloma. Report of 4 Cases. Insights in Blood Disorders. https://doi.org/10.33425/2771-9073.1012
Vancouver
Martinez RO, Islas PB, Rangel XC, Celaya ADLP, Muniz NR, Ibarra MA. Daratumumab Post Maintenance After Relapse in Multiple Myeloma. Report of 4 Cases. Insights in Blood Disorders. 2024. doi:10.33425/2771-9073.1012
BibTeX
@article{Martinez2024,
author = {Martinez, Roberto Ovilla and Islas, Pamela Baez and Rangel, Xochitl Cota and Celaya, Antonio de la Pena and Muniz, Nishalle Ramirez and Ibarra, Martha Alvarado},
title = {Daratumumab Post Maintenance After Relapse in Multiple Myeloma. Report of 4 Cases},
journal = {Insights in Blood Disorders},
year = {2024},
doi = {10.33425/2771-9073.1012}
}
EUVIMED